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E-mail address: galina.i.lepesheva@vanderbilt.eduCYP51 (sterol 14a-demethylase) is a cytochrome P450 enzyme essential for sterol biosynthesis and the
primary target for clinical and agricultural antifungal azoles. The azoles that are currently in clinical
use for systemic fungal infections represent modiﬁcations of two basic scaffolds, ketoconazole and ﬂuco-
nazole, all of them being selected based on their antiparasitic activity in cellular experiments. By studying
direct inhibition of CYP51 activity across phylogeny including human pathogens Trypanosoma brucei, Try-
panosoma cruzi and Leishmania infantum, we identiﬁed three novel protozoa-speciﬁc inhibitory scaffolds,
their inhibitory potency correlating well with antiprotozoan activity. VNI scaffold (carboxamide contain-
ing b-phenyl-imidazoles) is the most promising among them: killing T. cruzi amastigotes at low nanomo-
lar concentration, it is also easy to synthesize and nontoxic. Oral administration of VNI (up to 400 mg/kg)
neither leads to mortality nor reveals signiﬁcant side effects up to 48 h post treatment using an experi-
mental mouse model of acute toxicity. Trypanosomatidae CYP51 crystal structures determined in the
ligand-free state and complexed with several azole inhibitors as well as a substrate analog revealed high
rigidity of the CYP51 substrate binding cavity, which must be essential for the enzyme strict substrate
speciﬁcity and functional conservation. Explaining profound potency of the VNI inhibitory scaffold, the
structures also outline guidelines for its further development. First steps of the VNI scaffold optimization
have been undertaken; the results presented here support the notion that CYP51 structure-based rational
design of more efﬁcient, pathogen-speciﬁc inhibitors represents a highly promising direction.
 2012 Australian Society for Parasitology Published by Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
1.1. Human infections with Trypanosomatidae
Human infections with eukaryotic pathogens represent one of
the most severe global health problems. While fungal diseases re-
ceive signiﬁcant attention from pharmaceutical companies, the
pathologies caused by protozoan parasites are considered not
proﬁtable and remain highly ignored (Chaudhary and Roos,
2005). Chagas disease, sleeping sickness and leishmaniasis are
the three most neglected tropical diseases with the major impact
among the poorest (www.who.int/neglected_diseases/en/). The
etiologic agents are unicellular organisms from the orderPublished by Elsevier Ltd.
iochemistry, School of Med-
, TN 37232, USA. Tel.: +1615
(G.I. Lepesheva).
Open accKinetoplastida, family Trypanosomatidae: genera Trypanosoma and
Leishmania. Trypanosoma cruzi causes Chagas disease, endemic in
18 countries in South and Central America (www.who.int/
neglected_diseases/diseases/chagas/en). In this area, 8–10 million
people are infected, 50,000 die each year and >100 millions are
at risk. The disease is transmitted by kissing bugs (Triatomine);
other ways of infection include contaminated food, blood, organs
and from mother to child. In mammals, Trypanosoma cruzi cycles
as non-replicative bloodstream trypomastigotes and replicative
intracellular amastigotes. The severity of the acute stage varies
from non-symptomatic to fatal, depending on the parasite strain,
burden and host genetics. Chronic stage manifests 10–20 years
later, primarily affecting the heart and/or gastrointestinal tract.
Sleeping sickness is caused by Trypanosoma brucei and transmitted
by tsetse ﬂy (Glossina) (www.who.int/trypanosomiasis_african/en).
This parasite is extracellular, the bloodstream form eventually
crossing the blood-brain barrier and invading cerebrospinal ﬂuid.
Sleeping sickness is endemic in 36 African countries, withess under CC BY-NC-ND license.
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ple are at risk. Leishmania is transmitted by sand ﬂy (Plebotomine)
(www.who.int/leishmaniasis/en). In mammals these are obligatory
intracellular parasites, multiplying within macrophages. Depend-
ing on the Leishmania species, at least four different forms of the
disease can be distinguished. Visceral leishmaniasis (Leishmania
donovani, Leishmania infantum, Leishmania chagasi), also known as
kala-azar, or black fever, is the most severe form affecting visceral
tissues, primarily spleen, liver and bone marrow. Leishmaniasis is
endemic in 88 countries in Africa, America, Asia and Europe, with
12 million people infected, 1–2 million new cases and 60,000
deaths occurring each year. Without treatment, visceral leishman-
iasis, sleeping sickness and chronic symptomatic Chagas disease
are fatal. Due to human migrations and HIV-coinfections these dis-
eases are now spreading worldwide and becoming a real challenge
in North America, Europe and Asia. There are no vaccines (Cavalli
and Bolognesi, 2009), and a handful of drugs that have limited efﬁ-
cacy display severe side effects and high levels of resistance
(Lepesheva and Waterman, 2011a; Soeiro et al., 2009). Safer and
more efﬁcient drugs are desperately needed (Clayton, 2010; Leslie,
2011; Paniz Mondolﬁ et al., 2011) .1.2. Sterol biosynthesis and the CYP51 reaction
Sterols can be regarded as markers of eukaryotic cells (Rohmer
et al., 1979). They are essential membrane components and also
serve as regulatory (hormonal) molecules required for cell growth
and development (Nes, 2011). Beginning with acetyl-CoA conden-
sation, sterol biosynthesis proceeds to squalene 2,3-epoxide, which
in non-photosynthetic organisms is then converted into lanosterol,
the ﬁrst cyclized sterol precursor of the pathway (Fig. 1). The three-
step reaction shown in the black rectangle is catalyzed by aFig. 1. Schematic representation of sterol biosynthesis. Trypanosomatidae CYP51 subcytochrome P450 (CYP) monooxygenase, CYP51, also known as ste-
rol 14a-demethylase (EC 1.14.13.70) (Lepesheva and Waterman,
2007). As all cytochrome P450 enzymes, CYP51 is a cysteine-coor-
dinated hemoprotein, which cleaves molecular oxygen with the
formation of one molecule of water and insertion of the other oxy-
gen atom into the substrate. In order to fulﬁll its catalytic function
and remove the 14a-methyl group from the sterol ring, CYP51
must repeat one P450 catalytic cycle three times, with the sub-
strate molecule remaining properly oriented within the enzyme
active site for the three sequential monooxygenation steps. Being
an efﬁcient target for clinical and agricultural antifungals because
of its essentiality (Vanden Bossche, 1988), CYP51 is potentially
an excellent subject for further drug development. As a cyto-
chrome P450 it ‘‘senses’’ ligands spectrally, providing investigators
with basic information on the nature and binding afﬁnity of poten-
tial new inhibitors (Fig. 2).1.3. Protozoa-speciﬁc CYP51 inhibitory scaffolds
Using this approach as a starting point, we tested protozoan,
fungal and human CYP51s against commercial antifungals, experi-
mental azole derivatives, substrate analogs and also conducted
optical high throughput screening followed by web-search for
structurally similar compounds. As a result, novel CYP51 inhibitory
scaffolds have been identiﬁed, our current work being focused on
three of them (Fig. 3). VNI and VNF represent the most potent
inhibitory scaffold (Lepesheva et al., 2007): at the standard
CYP51 reaction conditions they completely inhibit activity of the
T. cruzi and T. brucei CYP51 orthologs at 1:1 molar ratio to the en-
zyme and cannot be replaced in the CYP51 active center by sub-
strate over time yet do not inhibit the human ortholog
(Lepesheva et al., 2008). Other important advantages of thisstrates, CYP51 reaction and the major end products of the pathway are shown.
Fig. 2. P450 spectral responses to ligand binding. (a) In the ferric (Fe3+) state CYP51 contains a water molecule (red sphere) coordinated to the heme iron (orange sphere);
low-spin hexacoordinated state, the Soret band maximum is at 417 nm. (b) When the iron is reduced (Fe2+) and binds CO, the Soret band maximum shifts to 450 nm. (c)
When the substrate (eburicol is shown in light blue) binds to the enzyme, it displaces water from the iron coordination sphere; Fe3+ becomes pentacoordinated high-spin, the
Soret band maximum shifts to the left (394 nm), producing type 1 spectral response. (d) When a ligand stronger than water directly coordinates to the heme iron (carbon
atoms of ﬂuconazole are colored in pink) the Soret band maximum shifts further to the right, producing type 2 spectral response. (e) Spectral responses of T. cruzi CYP51 to
two VNI derivatives, VNI-T and FF-VNI-T, and the corresponding titration curves. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to
the web version of this article.)
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which in comparison with cellular effect on T. cruzi amastigotes
(EC50 = 1.2 nM for VNI) (Lepesheva et al., 2011) produces selectiv-
ity index human/T. cruzi >50,000. Also, we found that, contrary to
the antifungal drugs posaconazole and ﬂuconazole, they do not in-
duce T. cruzi CYP51 gene expression, which suggests lower propen-
sity to cause resistance (Lepesheva et al., 2010a). Curative effect of
VNI in the murine model of Chagas disease has been conﬁrmed
(Villalta et al., in press) and its testing in the model of visceral
leishmaniasis is currently in progress. It is noteworthy that VNI
slows down parasitemia in the mouse model of T. brucei infection
(Lepesheva et al., 2010b), where endogenously produced T. brucei
sterols are required only for regulatory functions (Nes et al.,
2012); this ﬁnding advocates for a possibility of VNI use againstT. brucei in combination with the traditional anti-sleeping sickness
drugs.
1.4. Rigidity of the binding cavity as the most characteristic CYP51
structural feature
By the time when the ﬁrst eukaryotic CYP51 structures were
resolved (Lepesheva et al., 2010b), it was quite generally ac-
cepted that high ﬂexibility represents the major characteristic
feature of the cytochrome P450 structural fold (Poulos, 2003;
Scott et al., 2003; Williams et al., 2004; Ekroos and Sjögren,
2006), which ultimately meant that P450 structures are unlikely
to be reasonably helpful in directing rational design of new
P450-targeting inhibitors (Williams et al., 2004). However, we
Fig. 3. CYP51 inhibitors. (a) Antifungal drugs, posaconazole and ravuconazole have
entered clinical trials for Chagas disease. (b) Three novel experimental CYP51
inhibitory scaffolds. Indometacin amid derivatives (INDO-pyridine scaffold) are
interesting because of their potential dual action in vivo: as non-azole heme binding
CYP51 inhibitors and as COX2 inhibitors (anti-inﬂammatory effect) (Konkle et al.,
2009). 14a-Methylenecyclopropyl-24.25-dihydrolanosterol (MCP) acts as a T. cruzi
CYP51 selective suicide substrate, which is the ﬁrst example of an effective
mechanism-based CYP51 inhibitor (Hargrove et al., 2012). Carboxamide containing
b-phenyl imidazoles (VNI and VNF) are the most potent inhibitors of protozoan
CYP51s.
Fig. 4. CYP51 structure-based inhibitory pharmacophore. VNI (cyan, PDB ID: 3gw9),
VNF (salmon, PDB ID: 3ksw), MCP (green, PDB ID: 3p99) and a tipifarnib derivative
JKF (blue, PDB ID: 3tik) co-crystallized within the CYP51 binding cavity. The heme is
shown in yellow, the secondary structural elements that represent cytochrome
P450 substrate recognition sites (SRS) 1 (helix B0), 4 (helix I), 5 (b 1–4) and 6 (b 4-
hairpin) are depicted as ribbons. (For interpretation of the references to colour in
this ﬁgure legend, the reader is referred to the web version of this article.)
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CYP51s have a highly rigid substrate binding cavity. By determin-
ing X-ray structures of CYP51s from three protozoan pathogens
(T. brucei, T. cruzi and L. infantum), in ligand-free state [PDB ID:
3g1q] and complexed with different azole inhibitors ((Lepesheva
et al., 2010a,b; Hargrove et al., 2011; Buckner et al., in press),
and substrate analog MCP (Hargrove et al., 2012) we observed
that CYP51s do not reveal signiﬁcant conformational changes,
either upon ligand binding, or across species (Lepesheva and
Waterman, 2011b). This led us to the hypothesis that structural
rigidity of the CYP51 binding cavity (1) underlies the enzyme
ability to preserve strict catalytic conservation at very low se-
quence identity across phylogeny and (2) should allow prediction
of scaffold modiﬁcations that would potentially create a better
match of an inhibitor to the enzyme active site topology. Inter-
estingly, although VNI and VNF are structurally very similar
(Fig. 3), they bind to CYP51 in the opposite orientation, the
inhibitory pharmacophore (Fig. 4) revealing the empty volume
that extends beyond each of the bound inhibitors. First steps
for the CYP51 structure-based VNI scaffold modiﬁcation have
been undertaken and the results are presented below.2. Materials and methods
The proteins (T. cruzi, T. brucei, L. infantum, Candida albicans and
human CYP51s and rat and T. brucei cytochrome P450 reductase(CPR)) were expressed in Escherichia coli and puriﬁed as previously
described (Lepesheva et al., 2004, 2006; Hargrove et al., 2011).
P450 concentration was determined from reduced CO-binding
spectra using the coefﬁcient of molar extinction of De450–
490 = 911 cm1 (Omura and Sato, 1964).
2.1. Synthetic scheme and purity analysis of VNI and derivatives
The racemic mixture of VNI and its S-enantiomer was synthe-
sized by PyBOP amide coupling reaction between 1-(2,4-dichloro-
phenyl)-2-(1H-imidazol-1-yl)ethanamine 2 and 4-(5-phenyl-1,3,
4-oxadiazol-2-yl)benzoic acid 4. The compound 2 (Chevreuil et al.,
2006) was prepared from commercially available 1-(2,4-dichloro-
phenyl)-2-(1H-imidazol-1-yl)ethanol 1 in three steps starting with
mesylation with methanesulfonyl chloride in the presence of tri-
ethylamine to afford mesylated compound which was treated with
sodium azide, followed by reduction with lithium aluminum
hydride to provide compound 2 in 52% overall yield. Synthesis of
4-(5-phenyl-1,3,4-oxadiazol-2-yl)benzoic acid 4 commenced from
benzohydrazide 3 with methyl 4-(chlorocarbonyl)benzoate to af-
ford methyl 4-(2-benzoylhydrazinecarbonyl)benzoate. Oxadiazole
cyclization with POCl3 followed by hydrolysis with NaOH afforded
benzoic acid 4 in 90%.
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od and their S-enantiomers were separated by Supercritical Fluid
Chromatography (SFC).2.1.1. VNI
1H NMR (DMSO, 400 MHz) d (ppm) 9.39 (d, J = 8.0 Hz, 1H), 8.25
(d, J = 8.4 Hz, 2H), 8.16 (dd, J = 1.6, 8.0 Hz, 2H), 8.04 (d, J = 8.4, 2H),
7.76–7.59 (m, 5H), 7.51 (dd, J = 2.4, 8.4 Hz, 1H), 7.19 (s, 1H), 6.86 (s,
1H), 5.78–5.62 (m, 1H), 4.40 (dd, J = 10.0, 14.4 Hz, 1H), 4.31 (dd,
J = 5.2, 14.4 Hz, 1H); LCMS, single peak, 0.89 min, m/e, 504.2
(M+1); Chiral resolution, CHIRALPAK IB (4.6  250 mm) 50% iso-
cratic with 0.1 DEA.2.1.2. VNI-triazole
1H NMR (CDCl3, 400 MHz) d (ppm) 8.55 (d, J = 7.2 Hz, 1H), 8.27
(d, J = 8.4 Hz, 2H), 8.16 (dd, J = 2.0, 8.0 Hz, 2H), 8.11 (s, 1H), 8.06 (d,
J = 8.4 Hz, 2H), 7.87 (s, 1H, NH), 7.62–7.52 (m, 3H), 7.45 (d, J = 2.0
Hz, 1H), 7.07 (dd, J = 2.0, 8.4 Hz, 1H), 6.76 (d, J = 8.4 Hz, 1H),
6.02–5.93 (m, 1H), 4.75 (dd, J = 4.8, 14.4 Hz, 1H), 4.71 (dd, J = 3.6,
14.4 Hz, 1H); LCMS, single peak, 0.80 min,m/e, 506.1 (M+1); Chiral
resolution, CHIRALPAK IB (4.6  250 mm) 55% isocratic with 0.1
DEA.2.1.3. Diﬂuoro-b-phenyl-VNI-triazole
1H NMR (DMSO, 400 MHz) d (ppm) 9.29 (d, J = 8.4 Hz, 1H), 8.48
(s, 1H), 8.23 (d, J = 8.4 Hz, 2H), 8.15 (dd, J = 1.6, 8.0 Hz, 2H), 8.00 (d,
J = 8.4 Hz, 2H), 7.96 (s, 1H), 7.70–7.60 (m, 4H), 7.25 (dt, J = 2.4, 10.8
Hz, 1H), 7.15 (dt, J = 2.4, 8.4 Hz, 1H), 5.85–5.72 (m, 1H), 4.70 (dd,
J = 9.2, 13.6 Hz, 1H), 4.55 (dd, J = 5.6, 13.6 Hz, 1H); LCMS, single
peak, 0.72 min, m/e, 473.2 (M+1); Chiral resolution, CHIRALPAK
IB (4.6  250mm) 50% isocratic with 0.1 DEA.2.1.4. VNI/VNF combination
1H NMR (DMSO, 400 MHz) d (ppm) 8.24 (d, J = 8.4 Hz, 2H), 8.16
(d, J = 6.8 Hz, 2H), 7.96 (d, J = 8.4 Hz, 2H), 7.68–7.50 (m, 7H), 7.45
(d, J = 8.4 Hz, 1H), 7.42 (d, J = 12.0 Hz, 1H), 7.22–7.10 (m, 3H),
6.96 (s, 1H), 5.84 (t, J = 7.6 Hz, 1H), 4.63–4.45 (m, 2H); LCMS, single
peak, 0.75 min, m/e, 548.2 (M+1); Chiral resolution, CHIRALPAK IB
(4.6  250 mm) 55% isocratic with 0.1 DEA.2.2. CYP51 spectral titration
The titrations of CYP51s with VNI and its derivatives were car-
ried out in 2 ml tandem cuvettes at P450 concentrations of 2 lM
in the wavelength range 350–450 nm in a 50 mM potassium phos-
phate buffer, pH 7.4, containing 200 mM NaCl and 0.1 mM EDTA
using a Shimadzu UV-2401PC spectrophotometer. The inhibitors
were added to the sample cuvette in the concentration range
0.15–5.0 lM from a 0.2 mM stock solution in DMSO. The apparent
dissociation constants (Kd) were calculated by plotting the absor-
bance changes in the difference spectra (DA) upon titration against
free ligand concentration and ﬁtting the data to a rectangular
hyperbola in Sigma Plot Statistics as described previously (Lepesh-
eva et al., 2007). The concentrations of free ligand were calculated
using the equation:
½Lfree ¼ ½Ltotal  E  DA=DAmax
where [L] and [E] are the concentrations of the ligands (VNI deriva-
tives) and the enzyme used for the titration, respectively, DA is the
difference in the absorption observed at given ligand concentrations
andDAmax is the maximal difference in the absorption that has been
achieved upon titration.2.3. Reconstitution of CYP51 activity in vitro
The CYP51 reaction conditions were modiﬁed from those previ-
ously described (Lepesheva et al., 2007) in order to increase the ex-
cess of the substrate over the enzyme. In the standard reaction
mixture we use 1 lM CYP51 concentration, and therefore the max-
imal achievable enzyme/substrate ratio is 1/50 (due to low solubil-
ity of the CYP51 substrates). The modiﬁed reaction mixture
contained 0.1 lM CYP51, 2 lM CPR and 50 lM radiolabeled sterol
substrates, eburicol for T. cruzi, norlanosterol for T. brucei and L.
infantum and lanosterol for C. albicans and human CYP51 orthologs.
The inhibitors were added from 0.1 mM DMSO stocks to ﬁnal con-
centration 0.2 lM. The reaction was initiated by the addition of
100 lM NADPH, the mixture was incubated for 1 h at 37C. The
reaction was stopped by extraction of the sterols with ethyl ace-
tate. Reaction products were dried, dissolved in methanol, and ana-
lyzed by a reverse phase HPLC system (Waters) equipped with a b-
RAM detector (INUS Systems Inc.) using a Nova Pak C18 column
and linear gradient water:acetonitrile:methanol (1.0:4.5:4.5) (sol-
vent A) and methanol (solvent B) from 0% to 100% B for 30 min
at a ﬂow rate of 1 ml/min. Though at these conditions the CYP51
turnover became about 40-fold slower, we were able to see some
substrate conversion at 2/1 molar ratio VNI/CYP51 after 1 h reac-
tion. This increase in the sensitivity of the assay was used to
monitor inﬂuence of chemical modiﬁcations on the inhibitory
potencies of the VNI derivatives. The experiments were performed
in triplicates and presented as the mean ± standard deviation.
2.4. Cell culture and growth inhibition assay using 5-
bromodeoxyuridine incorporation
NIH/3T3 mouse embryonic ﬁbroblasts were purchased from
American Type Culture Collection (Manassas, VA). Cells were main-
tained in Dulbecco’s modiﬁed Eagle Medium (DMEM) containing
10% fetal bovine serum and 1% penicillin–streptomycin (Life Tech-
nologies, Gaithersburg, MD) at 37 C and in 5% CO2. NIH/3T3 cells
were plated in 96-well plates (5000 cells per well), incubated for
24 h and treated with vehicle (DMSO) or VNI derivatives for 24 h.
Incorporation of 5-bromodeoxyuridine (BrdU) was determined in
each well with the use of an enzyme-linked immunosorbent assay
(ELISA)-based 5-bromo-20-deoxy-uridine (BrdU) Labeling and
Detection Kit III (Roche Applied Science, Indianapolis, IN) according
to the manufacturer’s instructions. Brieﬂy, after treatment, cells
were labeled with BrdU for 16 h, ﬁxed, washed and incubated with
monoclonal anti-BrdU antibody conjugated with peroxidase for
90 min at room temperature. Then cells were washed and incu-
bated with substrate solution (TMB, tetramethyl-benzidine) for
5 min at room temperature. Reaction was stopped by addition of
1 M H2SO4, and optical density (OD) was measured immediately
at 450 nm using SpectraMAX 190 microplate reader (Molecular
Devices). BrdU incorporation was quantiﬁed by a change of OD.
Samples were analyzed in quadruplicates.
The cell growth inhibition effect was evaluated as percent of
proliferating cells (cells treated with VNI derivatives vs cells trea-
ted with DMSO; mean ± SEM). Since this method measures synthe-
sis of cellular DNA, i.e. the rate of cell growth and proliferation, it is
considered more sensitive in evaluation of cytotoxic effects com-
pared to cellular viability assays such as based on cell staining with
MTT or trypan blue. Therefore, it is more suitable to analyze com-
pounds with low cytotoxicity and/or without cytolytic activity.
2.5. Inhibitory effect on CYP3A4
The effect of VNI and its derivatives on the activity of human
CYP3A4 was compared with that of ketoconazole using a BD Biosci-
ences Screening Kit according to the manufacturer’s instructions.
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SpectraMax M5. Samples were analyzed in triplicates.
2.6. Acute mice toxicity study
Female Swiss Webster mice (25–26 g) were obtained from the
Fundação Oswaldo Cruz (CECAL-FIOCRUZ) animal facilities (Rio
de Janeiro, Brazil). Mice were housed at maximum 8 per cage
and kept in a conventional room at 20–24 C under a 12/12 h
light/dark cycle. The animals were provided with sterilized water
and chow ad libitum and all procedures were carried out in accor-
dance with the guidelines established by the FIOCRUZ Committee
of Ethics for the Use of Animals (CEUA 0028/09). In order to deter-
mine the NOAEL (No Observed Adverse Effect Level), acute toxicity
studies were performed as previously reported (Silva et al., 2008) .
Brieﬂy, on day 1, female mice were treated with VNI per oral (p.o.)
at doses ranging from 25 to 400 mg/kg. Then, mice were inspected
up to 48 h for toxic and sub-toxic symptoms according to OECD
guidelines (Organization for Economic Co-operation and Develop-
ment) (Batista et al., 2010). After this period, the NOAEL (no obser-
vable adverse effect level) values were determined, the animals
were euthanized and their blood and organs collected for hemato-
logical and biochemical measurements performed through the
Program for Technological Development in Tools for Health
(PDTIS-FIOCRUZ). Gross pathology and organ weight were also
evaluated as reported (Silva et al., 2012). The data are representa-
tive of three independent experiments and statistical analysis was
performed individually for each assay using a variance (ANOVA)
program with the level of statistical signiﬁcance set at p 6 0.05.a
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p < 0.05.3. Results and discussion
VNI ((R)-N-(1-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl)ethyl)-
4-(5-phenyl-1,3,4-oxadiazol-2-yl)benzamide) is a highly potent
inhibitor of protozoan CYP51s and represents a promising drug
candidate. We found that it has good oral bioavailability (>30%):
at a single dosage of 25 mg/kg its concentration in the mouse plas-
ma reaches 40 lM within 2 h and remains above 20 lM for 8 h
(Lepesheva and Hargrove, unpublished). Preliminary acute toxicity
studies demonstrate that the VNI dosages up to 400 mg/kg do not
cause signiﬁcant toxicity as no detectable side effect (including no
changes in characteristic mice behavior, motility, neurological con-
ditions, skin and fur proﬁle) could be noticed throughout the entire
period of analysis (48 h). The measurement of mice body weight
also did not reveal signiﬁcant alterations (Fig. 5a, p > 0.1). The gross
pathology did not show alterations in color and topological aspects
of the studied organs (spleen, lung, heart, liver and kidneys) as
compared to those mice that received vehicle (data not shown).
Regarding organ weight analysis (spleen, kidney, lung, heart and li-
ver), only a minor decrease (about 10%) in heart weight was de-
tected when the 25 and 400 mg/kg doses (p = 0.04 and 0.035,
respectively) were administrated (Fig. 5b). Also, a small variation
in liver size (increase <10%; p = 0.05) was detected using 200 mg/
kg VNI. Biochemical analysis of blood from VNI treated mice did
not demonstrate major differences as compared to the animals
treated with vehicle only (Table 1). Also, the analysis of alanine
aminotransferase (ALT) measurement did not suggest hepatic
damage since no signiﬁcant variations were found among VNI trea-
ted and DMSO-treated mice (Table 1). Altogether these data show           100                  200                  400
mg/kg) 
g/kg)
*
*
            100                    200                 400
idney Heart Lung
day 1 (starting at 25 mg/kg up to 400 mg/kg – p.o.) and then mice were inspected up
ndent assays showing the percentage (%) of animal body weight variation (0–48 h
alues of organ weight/body weight measurements after 48 h of VNI administration;
Table 1
Biochemical analysis of blood samples from control and VNI-treated female mice (n = 3).
VNI (mg/kg) 0 25 50 100 200 400
Red blood cells (million cells/mcL) 8.73 ± 0.8 8.19 ± 0.7 8.59 ± 0.6 8.76 ± 0.8 8.69 ± 0.7 7.97 ± 0.7
Hemoglobin (gm/dL) 15 ± 1.4 13.7 ± 1.1 14.6 ± 1.2 14.2 ± 1.3 14.1 ± 1.1 13.4 ± 1.2
Hematocrit (%) 49.7 ± 4.1 45.8 ± 3.7 48.4 ± 3.6 49.0 ± 4.1 48.8 ± 3.9 45.6 ± 4.0
Average red blood cell size (MCV – femtoliter) 56.9 ± 4.9 55.9 ± 4.7 56.3 ± 5.0 55.9 ± 4.3 56.2 ± 4.5 57.2 ± 4.7
Hemoglobin amount per red blood cell (MCH-pg/cell) 17.2 ± 1.4 16.7 ± 1.5 17.0 ± 1.4 16.2 ± 1.5 16.2 ± 1.3 16.8 ± 1.3
Amount of hemoglobin relative to the size of the cell (hemoglobin concentration) per
red blood cell (MCHC-gm/dL)
30.2 ± 2.7 29.9 ± 2.5 30.2 ± 3.0 29.0 ± 2.4 28.9 ± 2.4 29.4 ± 2.6
White blood cell (WBC-cells/mcL) 7.9 ± 0.7 9.6 ± 0.8 12.8 ± 1.1 13.3 ± 1.1 12.2 ± 1.0 9.4 ± 0.7
Platelets 1483 ± 118 1587 ± 127 1652 ± 139 1574 ± 126 1398 ± 110 1173 ± 95
Naa 156 ± 13 153 ± 13 152 ± 10 154 ± 11 152 ± 12 153 ± 11
Ka 9.5 ± 0.8 9.3 ± 0.7 7.9 ± 0.6 7.7 ± 0.6 8.0 ± 0.7 7.4 ± 0.7
Cla nd 91 ± 7 92 ± 9 92 ± 8 nd nd
Pa 13.7 ± 1.0 13.8 ± 1.1 12.8 ± 1.0 14.1 ± 1.4 13.2 ± 1.2 13.3 ± 0.9
Glucosea 199 ± 13 251 ± 19 211 ± 17 228 ± 15 262 ± 21 234 ± 18
Alanine aminotransferase (ALT)a 107 ± 7 nd 81 ± 6 78 ± 5 75 ± 6 82 ± 7
a Reference values (CECAL/Fiocruz): Na (124–174), K (4.6–8), Cl (92–120), P (6.1–10.1), glucose (90–192) and ALT (up to 132).
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mice, at 400 mg/kg via p.o., thus suggesting low toxicity.
However, VNI inhibits L. infantum CYP51 slightly weaker
(Table 2) than the two trypanosomal orthologs (perhaps because
of the larger volume of the L. infantum CYP51 substrate binding
cavity (Hargrove et al., 2011)). Also it would be potentially desir-
able to further increase the drug lifetime in plasma while weaken-
ing its inhibitory effect on CYP3A4 (the major drug metabolizing
cytochrome P450 in the human body).
The initial VNI modiﬁcations described here were undertaken
(1) to study whether the changes that improved the properties of
commercial antifungal azoles (Chen and Sorrell, 2007) (b-phenyl
ring ﬂuorination and replacement of the imidazole ring with the
1,2,4-triazole ring, see ketoconazole vs posaconazole and ravuco-
nazole in Fig. 3) will be favorable for the VNI scaffold as well;
and (2) to test whether ﬁlling the CYP51 substrate binding cavity
through VNI/VNF combination in one chemical structure such as
adding an additional aromatic ring to the b-phenyl rind (i.e. Table 2,
VNI/VNF) will further increase the inhibitory potency.
Variations in the heme-coordinating heterocyclic ring (imidaz-
ole vs triazole) were pursued to establish the signiﬁcance of the ba-
sicity of the iron-coordinating atom (imidazole > triazole) (El
Ghomari et al., 1997) and possible inﬂuence on the drug toxicity
(Zonios and Bennett, 2008), since it is generally believed that clin-
ical triazole antifungal drugs are less toxic and more selective than
imidazoles (Chen and Sorrell, 2007). Replacement of the Cl atoms
in the VNI b-phenyl ring by ﬂuorines was mainly aimed to examine
whether this substitution might ultimately be used to further en-
hance the compound pharmacokinetics (PK), particularly meta-
bolic stability in vivo (Zonios and Bennett, 2008; Hu et al., 2010)
without affecting CYP51 inhibition, since we already know that
minimal alterations in this ring composition are often crucial for
the inhibitory potency, sometimes assigning additional selectivity
to this scaffold (Lepesheva et al., 2007). Fluorine is now extensively
used in drug discovery and is increasingly found in drugs entering
the marketplace (Maddaford, 2012). It is quite well established
that the high electronegativity of ﬂuorine allows for manipulation
of drug properties including reduction of pKa, modiﬁcation of
lipophilisity, improving metabolic stability and duration of action
(Hagmann, 2008; Hu et al., 2010), enhancing potency, reducing
the potential for covalent protein binding and idiosyncratic toxic-
ity, attenuation of biliary clearance (Uetrecht, 2007), etc. Except
for FF-VNI, both R and S-enantiomers were tested to monitor inﬂu-
ence of stereochemistry on the compound properties. Ketocona-
zole was used as a control (Table 2).
Interestingly, all the derivatives displayed high apparent bind-
ing afﬁnity (shown in Table 2 for T. cruzi CYP51). Examples of
experimental titration curves for VNI-T (stronger inhibitor,Kd = 0.15 lM) and FF-VNI-T (weaker inhibitor, Kd = 0.07 lM) are
presented in Fig. 2e. The data support our previous ﬁnding that
coordination of the N atom to the heme iron which is reﬂected in
the spectral responses, being useful for primary identiﬁcation of li-
gand binding, does not necessarily correlate with the inhibitory po-
tency of the compound in the reconstituted enzyme reaction, as
some of the ligands can be later replaced by the substrate in the
enzyme active center (Lepesheva et al., 2007).
3.1. VNI-triazole (VNI-T)
Signiﬁcant decrease in the cellular growth inhibition was the
most obvious advantage of the heme coordinating ring modiﬁca-
tion (98% of proliferating cells for 50 lM VNI-T vs. 77% for 50 lM
VNI, Table 2). However, no increase in the inhibitory potency
was observed. While T. cruzi and L. infantum CYP51s presented
about the same values as those obtained with VNI, the T. brucei
ortholog inhibition with VNI-T was much weaker. Quite unexpect-
edly, T. brucei CYP51 was more strongly inhibited by the S-enantio-
mer, which affected the other protozoan CYP51s relatively weaker
than the S-enantiomer of VNI. Thus, the basicity of the heterocyclic
nitrogen does not seem to be crucial for CYP51 inhibition, at least
for the VNI scaffold. This is in agreement with the hypothesis that
it must be the interaction of the nonligated portion of the azole
molecule with the protein moiety which deﬁnes the compound
inhibitory potency (Correia and Ortiz de Montellano, 2005). Over-
all, the data suggest that VNI-T is worth testing as a drug candidate
for Chagas disease and leishmaniasis, particularly because of
potentially greater safety.
3.2. Diﬂuoro-b-phenyl-VNI (FF-VNI)
Although in the CYP51 structures the b-phenyl rings of posaco-
nazole and VNI are positioned similarly (Lepesheva et al., 2010a),
substitution of the two Cl atoms to ﬂuorines in the VNI scaffold
did not display any advantages. Only for the T. cruzi enzyme the
potency of FF-VNI was comparable to that of VNI, while the other
orthologs were inhibited weaker. Also, our preliminary studies of
FF-VNI PK did not reveal any improvement (not shown), which im-
plies that the primary site(s) of in vivo metabolism in the VNI scaf-
fold must be different from that of the posaconazole/ravuconazole
scaffolds and needs to be identiﬁed prior to further introduction of
the ﬂuorine atoms.
3.3. Diﬂuoro-b-phenyl-VNI-triazole (FF-VNI-T)
The ﬁnding that the b-phenyl ring is not the right place for the
replacement of Cl to F in VNI was further conﬁrmed upon testing of
Table 2
VNI and its derivatives as CYP51 inhibitors.
Effect Compound
VNI S-enan-
tiomer
FF-VNI VNI-T S-enan-
tiomer
FF-VNI-T S-enan-
tiomer
VNI/VNF S-enan-
tiomer
Ketoco-
nazole
Binding to T. cruzi CYP51,
Kd (lM)
0.09 ± 0.01 0.12 ± 0.01 0.02 ± 0.006 0.15 ± 0.012 0.55 ± 0.04 0.07 ± 0.01 0.17 ± 0.02 0.04 ± 0.007 0.10 ± 0.01 0.24 ± 0.02
CYP51 inhibition
Pathogens (activity at I/E/Sa = 2/1/500, 60’ reaction, %)
T. cruzi 7 ± 0.5 17 ± 1.5 9 ± 0.7 8 ± 0.6 70 ± 4.3 90 ± 6.7 85 ± 6.4 0 26 ± 1.7 38 ± 2.8
T. brucei 2 ± 0.1 65 ± 5.8 11 ± 109 90 ± 6.4 56 ± 3.8 93 ± 8.0 83 ± 6.6 0 74 ± 5.3 54 ± 3.9
L. infantum 12 ± 1.1 96 ± 6.3 58 ± 4.9 17 ± 1.2 97 ± 7.1 68 ± 5.1 95 ± 7.4 2 ± 0.2 32 ± 2.2 24 ± 1.6
C. albicans 40 ± 3.4 nt 68 ± 5.5 100 ± 6.9 75 ± 5.7 100 ± 7.7 95 ± 6.9 30 ± 2.4 90 ± 6.7 9 ± 0.
Human (inhibitor/
enzyme molar ratio for
50% inhibition, 60’
reaction)
>200 >200 >200 >200 >200 >200 >200 15 ± 0.9 >200 80 ± 5.9
Mammalian cell growth:
% of viable 3T3 cells at
50 lMb
76.8 ± 2.1 77.1 ± 2.6 65.9 ± 3.1 98.1 ± 1.8 97.9 ± 1.9 101.0 ± 1.4 107.2 ± 1.7 77.2 ± 6.3 74.6 ± 5.4 0
LogP (ChemDraw) 4.6 4.6 3.7 4.9 4.9 4.1 4.1 5.4 5.4 3.5
CYP3A4 inhibition
(IC50, nM)
405 ± 23 290 ± 19 180 ± 14 2910 ± 227 2370 ± 152 nt nt 3580 ± 271 2040 ± 16 8 ± 0.7
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Chiral atom (VNI and all other structures shown are R-enantiomers).
a Molar ratio inhibitor/enzyme/substrate; experimental details can be found in Section 2.
b The concentration range was limited by the compound solubility in DMSO (5 mM for the imidazole and 20 mM for the triazole derivatives), maximal DMSO concentration
in the cell cultures not exceeding 1%.
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for all pathogenic CYP51s, though the fact of the decrease in toxic-
ity as a result of the triazole ring presence was conﬁrmed (Table 2).
3.4. VNI/VNF combination (VNI/VNF)
The compound which was designed based on the structures of
CYP51 complexes with VNI [3gw9] and VNF [3ksw] with the pur-
pose to ﬁll the majority of the CYP51 substrate binding cavity
was indeed found to be the most potent inhibitor of all three pro-
tozoan CYP51s. Its effect on C. albicans CYP51 (structure not yet
determined) remains relatively weaker than the effect of ketocon-
azole. VNI/VNF also inhibits human CYP51 stronger than the other
VNI derivatives (Table 2). It remains to be clariﬁed (and is a good
opportunity to do so) whether the observed decrease in selectivity
might have any harmful effect in mammals in vivo, though we
anticipate that replacement of the imidazole ring in VNI/VNF with
the triazole ring should increase the inhibitor selectivity while
further decreasing its toxicity and inhibitory effect on CYP3A4.
The S-form of this compound, similar to the S-enantiomer of VNI,
displays a weaker inhibitory potency towards all three protozoan
CYP51s.
To conclude, the VNI scaffold is highly promising for the devel-
opment of novel drugs for human infections with Trypanosomati-
dae. CYP51 structure can successfully be used to guide further,
rational development of this scaffold in order to produce highly
selective, pathogen-speciﬁc drugs.
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